For Patients April 2026

Russian Oncovaccines for Melanoma and Colorectal Cancer: Neoonkovak, Onkopept, Onkorna, and EnteroMix

Questions about cancer vaccines come up very often these days — not only from patients and family members but from physicians, healthcare administrators, and insurance company staff. In oncology, personalized vaccines sound like hope, especially when standard treatment has been completed or when the risk of recurrence remains high.

In April 2026 the topic became particularly visible. Russia’s Ministry of Health reported the first clinical use of the personalized mRNA vaccine Neoonkovak in a patient with skin melanoma. A few days later came an announcement that treatment with Russian oncovaccines could be available under the national health insurance system (OMS). The Federal Medical-Biological Agency (FMBA) reported regulatory clearance for clinical use of the mRNA vaccine Onkorna for colorectal cancer and the first administration of the peptide vaccine Onkopept.

While all of this sounds promising, it is important to understand that regulatory clearance, insurance coverage, first patients, and good news on tolerability are not the same as proven efficacy. Between hope and a new standard of care in oncology, there must always be data — typically randomized trials with a control group, clear endpoints (overall and disease-free survival, recurrence risk, objective response), and toxicity data.

What Happened, in Brief

On April 1, 2026, the Ministry of Health announced the first administration of the personalized mRNA vaccine Neoonkovak to a patient with skin melanoma — a 60-year-old man from Kursk region (Interfax).
On April 6, 2026, the Prime Minister stated that treatment using Russian oncovaccines may be available under the OMS insurance system for selected oncologic conditions, initially focusing on certain blood cancers and cancers of internal organs (Interfax).
The National Medical Research Center for Radiology describes Neoonkovak as a personalized neoantigen mRNA vaccine for treatment of stage IIB–IV skin melanoma, used in combination with immune checkpoint inhibitors. Manufacturing requires tumor tissue and takes 3–4 months (NMRC Radiology).
FMBA reported regulatory clearance for clinical use of Onkorna, a personalized mRNA vaccine for colorectal cancer, and the first administration of Onkopept, a personalized peptide vaccine (Interfax).
EnteroMix is often discussed alongside oncovaccines, but it is a different type of product: an oncolytic agent based on enteroviruses. The Russian registry lists an open single-center Phase 1 study with planned enrollment of 48 patients with solid tumors (Russian registry).

Key Figures and Data Available in Open Sources

Neoonkovak

Neoonkovak is described as a personalized antitumor mRNA vaccine, manufactured individually based on the patient’s tumor molecular-genetic profile. The Ministry of Health announcement (via Interfax) describes the first clinical administration in a patient with skin melanoma. Unfortunately, data on overall and disease-free survival, progression-free survival, or objective response are not provided.

The NMRC Radiology page lists potential patient groups: adults with unresectable or metastatic skin melanoma in combination with immune checkpoint inhibitors, and adults after resection of all metastatic foci, in adjuvant combination with checkpoint inhibitors. Tumor tissue is required for manufacturing, and the vaccine is added 3–4 months after tissue procurement (the time needed to produce it).

Neovak-RONC

Separately, the Ministry of Health authorized the use of an individualized biotechnological drug Neovak-RONC — a personalized mRNA vaccine for melanoma therapy, manufactured by N. N. Blokhin National Medical Research Oncology Center. The TASS report includes an important caveat: this is only the beginning of using this approach, and efficacy and safety still need to be evaluated.

The Blokhin Center page indicates that the antitumor mRNA vaccine will be used in patients with skin melanoma in adjuvant settings, in combination therapy under a research protocol. A medical board (consilium) decides on inclusion in the protocol.

Onkorna

FMBA announced that Onkorna received regulatory clearance for clinical use in colorectal cancer therapy. The drug is described as a personalized mRNA vaccine based on lipid nanoparticles containing synthesized mRNA encoding the patient’s individual neoantigenic tumor peptides.

In FMBA’s open communication the proposed indications are: adults with metastatic colorectal cancer after two or more lines of systemic therapy, and patients with microsatellite instability-high (MSI-H) colorectal cancer in combination with immune checkpoint inhibitors. Survival, response, and safety data are not provided.

Onkopept

Onkopept is described as a personalized oncovaccine for treatment of colorectal cancer. According to FMBA, the first patient received the drug on March 31, 2026, and by April 13 had received three administrations. Tolerability was described as good. It was also reported that 543 inquiries were processed, 24 patients selected, and that vaccine production takes 49 days, including at least 7 days of quality control.

It is important to recognize that good tolerability in a first patient is, of course, an early safety signal, but not an answer about efficacy. From open sources it is not yet possible to say whether Onkopept reduces the risk of progression, reduces tumor burden, prolongs life, or lowers the risk of recurrence.

EnteroMix

EnteroMix should be considered separately. The Russian registry lists an open single-center Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of EnteroMix — based on enteroviruses — in patients with histologically confirmed solid tumors. The study is in active enrollment with a planned 48 participants. It started on November 1, 2024 and is planned to complete on October 1, 2026.

The primary objective of the EnteroMix study is to evaluate the safety and tolerability of different doses and administration regimens. Secondary objectives include pharmacokinetics, evaluation of therapeutic activity, and biological markers. This is a Phase 1 study, not a study designed in principle to determine efficacy.

Why This Matters for Practice

The weak spot of Russian oncovaccines is the absence of open efficacy data. Clinical practice should not change merely because of headlines. For a method to become a new standard, data are needed that allow comparison of the new therapy against the best available standard of care. In oncology, this typically means a randomized trial, a control arm, clear endpoints, and published results.

A good example of the level of evidence to which modern oncology usually aspires is the KEYNOTE-942 / mRNA-4157-P201 trial. It compared neoantigen mRNA therapy mRNA-4157/V940 plus pembrolizumab (Keytruda) with pembrolizumab alone in 157 patients with completely resected high-risk stage IIIB–IV melanoma. In this Phase 2b study, 18-month recurrence-free survival was 79% vs 62% (HR 0.561, 95% CI 0.309–1.017, p=0.053). Even this is not yet a complete answer to all questions, but it is a published randomized data format that can be discussed scientifically.

Limitations / What Does Not Change Yet

In open sources on Russian oncovaccines there are currently reports of regulatory clearances, patient routing, first patients, preclinical data, selection criteria, and certain manufacturing parameters. But for most key clinical questions there is not yet published data in the format expected by evidence-based oncology.

Inclusion under the OMS insurance system does not mean that treatment is suitable for every patient or available at any clinic. It means that a specific type of high-tech care can be paid for under defined rules — but does not eliminate medical selection, the consilium decision, inclusion criteria, the need for tumor material, or risk assessment.

Even the available data do not apply to all cancer types. Neoonkovak and Neovak-RONC are linked primarily to melanoma. Onkopept and Onkorna — to colorectal cancer. EnteroMix is being studied in patients with solid tumors in a Phase 1 trial focused on safety and tolerability.

Standard therapy must not be discontinued on one’s own in favor of an oncovaccine. For melanoma there are already proven options — PD-1 inhibitors, immunotherapy combinations, BRAF/MEK inhibitors for BRAF V600 mutation, and surgery. For colorectal cancer, strategy depends on stage, molecular profile, MSI status, RAS and BRAF mutations, HER2, NTRK, prior treatment lines, and the patient’s overall condition.

Initial tolerability data are not equivalent to a full safety profile. Toxicity assessment requires dozens to hundreds of patients, standardized adverse event reporting, long-term follow-up, and the ability to distinguish what is related to the vaccine, what to concomitant immunotherapy, and what to disease course.

As a physician, I view these data with interest — but without unnecessary excitement or optimism. Personalized vaccines are genuinely a promising direction. But in oncology, hope must be tested by evidence. So far we see the beginning of clinical use, individual administrative decisions, a preclinical base, an early-phase trial for EnteroMix, and first patient reports. This is not enough to tell a patient that something works better than standard care.

Conclusion

Russian oncovaccines, however promising they may seem, should not yet be viewed as universal cancer treatment. The right position for patients now is not to abandon standard therapy, not to make decisions based on headlines, but to discuss treatment options with their physician — by reviewing the diagnosis, stage, biomarkers, prior treatment, and the real applicability of new approaches.

When a Second Opinion Is Especially Helpful

if a patient has stage IIB–IV melanoma and adjuvant therapy, immunotherapy, or participation in a research protocol is being discussed
if a patient has metastatic colorectal cancer after several lines of treatment and is considering Onkopept, Onkorna, a clinical trial, or an experimental approach
if key biomarkers are missing — BRAF, MSI, RAS, NRAS, HER2, NTRK, or others in colorectal cancer
if the patient is considering postponing or stopping standard therapy while waiting for an oncovaccine
if there is a loud promise, a fundraising campaign, an offer of urgent travel, or an unclear treatment route — but no demonstrated evidence of efficacy

Read more about how a second opinion works and when it is useful.

What to Prepare for the Consultation

histology report
immunohistochemistry report, if performed
records of all stages of treatment
surgical or biopsy report
CT, MRI, PET-CT scans with serial imaging
discs or electronic image files
molecular testing results
biomarker data: BRAF, MSI, RAS, NRAS, HER2, NTRK, PD-L1 and others if performed
information on whether tumor material has been preserved
recent blood tests
list of comorbidities and continuously taken medications

Sources:

If you have melanoma, colorectal cancer, or another solid tumor, and an oncovaccine, clinical protocol, OMS-based treatment, repeat biopsy, or change of therapy is now being discussed, you can come for a consultation or get a second opinion. We can review the clinical situation, stage, molecular profile, prior treatment, availability of preserved tumor material, and form an understanding of how applicable the new data are to your specific situation.

Frequently Asked Questions

Does an oncovaccine apply to every cancer patient?

No. The Russian developments currently being discussed publicly cover different diseases and clinical situations. Neoonkovak and Neovak-RONC are linked primarily to melanoma; Onkopept and Onkorna to colorectal cancer; EnteroMix is being studied in patients with solid tumors in a Phase 1 trial. There is no universal vaccine for any cancer right now.

Is this already a new standard of care?

Not yet. A new standard requires published clinical data with a clear comparison against standard therapy. At present, public information about Russian oncovaccines mainly consists of regulatory clearance announcements, patient routing, first administrations, preclinical data, and early studies. This is an important step but not proof of efficacy.

Can the oncovaccine be obtained under public insurance (OMS)?

It has been announced that treatment using Russian oncovaccines may be available under OMS for selected clinical situations. But there is no data yet showing availability for all patients. Indications, eligibility criteria, a multidisciplinary board decision, availability of tumor tissue, and a clear referral route within a specialized center are required.

How does EnteroMix differ from oncovaccines?

EnteroMix is an oncolytic enterovirus-based agent, not a personalized mRNA or peptide vaccine. According to the Russian registry, an open single-center Phase 1 study is ongoing in 48 patients with solid tumors. The main objective of such a phase is safety and tolerability — not a definitive efficacy answer.

Should treatment be changed urgently if I match the diagnosis?

No. The decision cannot be made based solely on having a particular diagnosis. Stage, disease extent, prior therapy, mutations, MSI status, overall condition, disease tempo, availability of standard options, and the time required to manufacture an individualized product all matter. Standard therapy must not be discontinued on one’s own.